# Florastamin F-18

Source: https://onco.cc/drugs/florastamin-f18/  
OnCo record `florastamin-f18` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Florastamin is FutureChem's fluorine-18 PSMA PET tracer from South Korea, in phase 3 trials for staging high-risk and recurrent prostate cancer alongside the established PSMA agents.

## Summary

FutureChem, a Seoul radiopharmaceutical company, developed florastamin (FC303) as a fluorine-18 PSMA ligand for PET imaging of prostate cancer. Registered phase 3 trials assess it for initial staging of high-risk prostate cancer and for biochemical recurrence, the settings in which gallium-68 PSMA-11 and piflufolastat are already approved in the United States and Europe.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Code: FC303
- Modality: PSMA-targeted PET radiotracer, fluorine-18
- Mechanism: A fluorine-18-labelled ligand of prostate-specific membrane antigen that lights up prostate cancer on PET wherever it has spread.

## Sources

- ClinicalTrials.gov: trials of Florastamin F-18: https://clinicaltrials.gov/search?intr=FC303

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [PET (positron emission tomography)](https://onco.cc/technologies/pet/), [PSMA PET](https://onco.cc/technologies/psma-pet/)
- targets: [PSMA](https://onco.cc/targets/psma/)
- trials: [[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer](https://onco.cc/trials/nct05936658/), [Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis](https://onco.cc/trials/nct05004285/)

---
JSON: https://onco.cc/api/v1/entities/florastamin-f18.json